Lachmann HJ - Search Results

1

Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?

Razvi Y, Ioannou A, Patel RK, Chacko L, Karia N, Riefolo M, Porcari A, Rauf MU, Starr N, Ganesananthan S, Blakeney I, Kaza N, Filisetti S, Bolhuis RE, Rowczenio D, Gilbertson J, Hutt D, Mahmood S, Lachmann HJ, Wechalekar AD, Kotecha T, Knight DS, Coghlan JG, Petrie A, Whelan CJ, Venneri L, Martinez-Naharro A, Hawkins P, Fontana M, Gillmore JD. Razvi Y, et al. Among authors: lachmann hj. Eur J Heart Fail. 2024 Feb;26(2):383-393. doi: 10.1002/ejhf.3088. Epub 2024 Jan 28. Eur J Heart Fail. 2024. PMID: 37953725

2

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.

Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Lachmann HJ, et al. N Engl J Med. 2002 Jun 6;346(23):1786-91. doi: 10.1056/NEJMoa013354. N Engl J Med. 2002. PMID: 12050338 Free article.

3

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Lachmann HJ, et al. Br J Haematol. 2003 Jul;122(1):78-84. doi: 10.1046/j.1365-2141.2003.04433.x. Br J Haematol. 2003. PMID: 12823348 Free article.

4

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.

Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN. Gillmore JD, et al. Among authors: lachmann hj. Blood. 2006 Feb 1;107(3):1227-9. doi: 10.1182/blood-2005-08-3253. Epub 2005 Oct 6. Blood. 2006. PMID: 16210334 Free article.

5

AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases.

Lachmann HJ, Goodman HJ, Andrews PA, Gallagher H, Marsh J, Breuer S, Rowczenio DM, Bybee A, Hawkins PN. Lachmann HJ, et al. Arthritis Rheum. 2006 Jun;54(6):2010-4. doi: 10.1002/art.21901. Arthritis Rheum. 2006. PMID: 16732551 Free article.

6

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK.

Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Goodman HJ, et al. Among authors: lachmann hj. Br J Haematol. 2006 Aug;134(4):417-25. doi: 10.1111/j.1365-2141.2006.06204.x. Epub 2006 Jul 5. Br J Haematol. 2006. PMID: 16822290 Free article.

7

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Wechalekar AD, et al. Among authors: lachmann hj. Blood. 2007 Jan 15;109(2):457-64. doi: 10.1182/blood-2006-07-035352. Epub 2006 Sep 21. Blood. 2007. PMID: 16990593 Free article. Clinical Trial.

8

Natural history and outcome in systemic AA amyloidosis.

Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Lachmann HJ, et al. N Engl J Med. 2007 Jun 7;356(23):2361-71. doi: 10.1056/NEJMoa070265. N Engl J Med. 2007. PMID: 17554117 Free article.

9

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Lachmann HJ, Wechalekar AD, Gillmore JD. Lachmann HJ, et al. N Engl J Med. 2008 Jan 3;358(1):91-2; author reply 92-3. N Engl J Med. 2008. PMID: 18175386 No abstract available.

10

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.

Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Wechalekar AD, et al. Among authors: lachmann hj. Haematologica. 2008 Feb;93(2):295-8. doi: 10.3324/haematol.11627. Haematologica. 2008. PMID: 18245653 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters